Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in metastatic disease and Keynote 522 for TNBC (Pembrolizumab) neoadjuvant therapy.
Link to DESTINY-Breast03 –
https://clinicaltrials.gov/ct2/show/NCT03529110
Link to KEYNOTE-522 –
https://clinicaltrials.gov/ct2/show/NCT03036488
Link to SABCS 2021 –
https://www.sabcs.org/2021-SABCS